1. Introduction {#sec1}
===============

Malaria remains a global problem with 219 million cases reported in 2017, 92% of which were in Africa \[[@B1]\]. Similarly, Africa has the highest incidence of tuberculosis (TB) cases at 237 per 100,000 population with 25% of the incident cases globally \[[@B2]\]. Uganda is among the 5 countries that contribute nearly half of the global malaria cases despite 90% of households owning insecticide treated mosquito nets \[[@B1], [@B3]\]. The geographical overlap of malaria and TB especially in areas with high incidence of HIV creates a possibility of a malaria/TB coinfection and malaria/TB/HIV triple infection \[[@B4], [@B5]\]. However, there are few epidemiological studies of malaria among TB patients. The few studies available report the prevalence of malaria among TB patients to be between 1.5 and 93.7% \[[@B6]--[@B10]\]. These are limited by heterogeneity considering that one of the studies used serological prevalence, two included clinically diagnosed TB patients, and another was carried out on Egyptian mummies. An attendant problem with malaria among TB patients is the overlap of symptoms, clinical signs, and complications such as anaemia, cough, and respiratory distress \[[@B11], [@B12]\]. This delays the diagnosis and initiation of treatment of either infection, yet malaria has the potential to increase mortality of TB patients \[[@B13]\]. The increase in mortality is plausibly due to deleterious immune interactions between TB and malaria which have not been studied widely in human subjects. Old studies among malaria/TB coinfected murine models suggested protective humoral and cellular immune responses against the complications of each disease \[[@B14], [@B15]\]. However, new evidence suggests that malaria increases mortality and morbidity of TB subjects by increasing bacillary load, hemozoin loading of macrophages, disruption of the TB granuloma, and altered T-cell responses \[[@B16]--[@B18]\]. TB reduces CD4 and CD8 counts and the CD4:CD8 ratio independently of malaria \[[@B19]--[@B21]\]. Similarly, malaria has been reported to reduce the CD4 and CD8 counts and the CD4:CD8 ratio \[[@B22], [@B23]\]. It is therefore crucial to investigate the immune effects of malaria and TB coinfection on the CD4 and CD8 cells which have a key role in TB immune responses alongside macrophages and other innate immune mechanisms \[[@B24]\]. This becomes imperative in the HIV/AIDS era because HIV is a major risk factor for TB reactivation by depleting CD4 cells, and malaria/TB/HIV triple infection could worsen the immune suppression \[[@B4], [@B26]\].

Understanding the prevalence, clinical factors, and immunologic interaction of malaria and TB presents an opportunity for early diagnosis, control, and eradication of two notorious diseases that present a global emergency. The primary aim of the study was to determine the prevalence of malaria/TB coinfection among bacteriologically confirmed adult TB patients at a national TB treatment centre in Uganda.

2. Materials and Methods {#sec2}
========================

2.1. Study Population and Setting {#sec2.1}
---------------------------------

We used a cross-sectional study design and consecutively enrolled 363 bacteriologically confirmed TB patients presenting to the admission facility or outpatient clinics of the Mulago Hospital tuberculosis treatment unit between August 2017 and March 2018. Mulago Hospital is the national referral hospital in Uganda located in Kampala, the capital city of Uganda. The Mulago Hospital TB unit is the national TB treatment centre for adult susceptible and drug resistant TB patients and treats 25% of the country\'s TB cases. Bacteriologically confirmed TB patients are referred from across the country with laboratory results for sputum microscopy, a nucleic acid amplification test (NAAT), or mycobacterial culture performed from the laboratory of the referring health facility. Bacteriologic confirmation of tuberculosis at the national TB treatment centre is performed only for patients primarily presenting for diagnostic workup at the centre unless special circumstances dictate a repeat evaluation of the sputum results from a referring health facility. We included participants aged 18 years and above, who had pulmonary bacteriologically confirmed TB by a positive sputum smear, culture, or NAAT and consented to participate in the study. Participants that had received TB treatment for 2 weeks prior to the study were excluded as TB treatment significantly reduces bacillary load and immune responses after 2 weeks \[[@B27], [@B28]\]. Study participants were identified from the TB unit and laboratory registers of the TB unit at Mulago Hospital every working day of the week and were enrolled until the desired sample size was obtained.

2.2. Study Measurements {#sec2.2}
-----------------------

A pretested structured questionnaire was administered in a face to face interview by a research assistant to obtain medical history and clinical symptoms. Seven symptoms (cough, fever, night sweats, weight loss, anorexia, headache, and chills) and their duration in days were asked of the study participants. We arbitrarily considered having 4 or more symptoms as a high symptom burden while having less than 4 symptoms was considered as a low symptom burden. The bacillary load was determined by Xpert MTB/RIF® and Ziehl-Neelsen (ZN) or Auramine sputum smear for 84% (304/363) and 14% (46/363) of study participants, respectively. This was extracted from the laboratory results from the referring health facility or the Mulago Hospital tuberculosis treatment centre laboratory. Across the country, standard techniques are employed in the laboratory diagnosis of tuberculosis according to national and World Health Organisation (WHO) recommendations \[[@B29], [@B30]\]. For 12 participants, GeneXpert was reported as "*Mycobacterium tuberculosis* (MTB) detected" while for the only participant with a culture result, it was reported as "positive". For these 13 participants, the bacillary load grade could not be established. Bacillary load grade was standardised as shown in [Table 1](#tab1){ref-type="table"}.

A calibrated weighing scale and stadiometer (Seca 760® and Seca 213®, respectively) were used to measure the patient\'s weight and height to calculate the body mass index (BMI) using the formula BMI = weight (kg)/height (meters)^2^. A BMI less than 18.5 kg/m^2^ was considered underweight, 18.5 to 24.9 kg/m^2^ was considered normal, and 25 to 29.9 kg/m^2^ was considered overweight while above 30 kg/m^2^ was considered obese. A digital thermometer (Royal Care® Model: MT 1027, SOJOY ELECTRONICS, China) was used to measure axillary temperature. A temperature of less than 35.5°C was considered as hypothermia, 35.5°C to 37.4°C as normal, above 37.4°C but less than 41.5°C as hyperthermic, and equal or above 41.5°C as hyperpyrexia.

A study nurse drew 5 milliliters of blood following standard procedures. Malaria was determined by thick and thin blood smears. A malaria antigen rapid diagnostic test (RDT) (SD BIOLINE Malaria Ag P.f/Pan®) was performed only when the smear was negative. Using RDT is justifiable as the immune effects of malaria on TB may last up to 5 months after the malaria infection has cleared \[[@B31]\]. One was considered to have malaria if either a thick blood smear or a rapid diagnostic test was positive. In the preparation of the thick blood smear, peripheral blood films were made from fresh EDTA blood onto clean glass slides. These were air-dried and fixed with absolute methanol for 3 minutes. They were then stained with freshly prepared Giemsa stain for 10 minutes at a pH of 6.8 before being washed off by tap water. The films were then further differentiated in buffered water (pH 6.8), washed, and air-dried. A laboratory haematologist examined the films using a binocular microscope using 100X objective. Red blood cells (RBCs) were examined to determine the type of anaemia, for hemoparasites screening and typing. White cell and red cell counts were read off the hemogram as analysed by a hemoanalyser (Sysmex® Automated haematology analyser XN series -- XN 1000) at Mulago Hospital Haematology Laboratory. A hemoglobin level was read from the hemogram. It was classified according to the WHO guidelines \[[@B32]\] as follows: mild anaemia was 11.00 to 13 grams per decilitre (g/dl) for a male individual and 11.00 to 12 g/dl for females; moderate anaemia was 8.00 to 11 g/dl (both sexes); and severe anaemia meant hemoglobin less than 8 g/dl for both sexes. Anaemia was classified as microcytic if the mean corpuscular volume (MCV) was less than 76 femtoliters (fl) or macrocytic if MCV was above 96 fl. It was classified as hypochromic if mean cell hemoglobin (MCH) was below 24 picograms (pg). These were also read off the hemogram, and hypochromia was confirmed on peripheral film examination. CD4 and CD8 counts were measured for all study participants by flow cytometry using a flow cytometer (BD FACSCalibur™) at Makerere University joint AIDS program laboratory. The normal CD4 and CD8 counts and CD4:CD8 ranges for this study were 418-2105 cells per microliter (*μ*l), 256-1619 cells/*μ*l, and 0.52-4.1, respectively, according to the Ugandan population estimates \[[@B33]\]. An HIV test was performed on all participants\' serum using an immunochromatographic rapid test (Alere Determine™ HIV-1/2), and a positive test was confirmed by sequential testing with another immunochromatographic test (Chembio HIV 1/2 STAT-PAK™) following the Uganda national HIV testing algorithm \[[@B34]\].

2.3. Sample Size Estimation and Statistical Analysis {#sec2.3}
----------------------------------------------------

The sample size estimation was informed by the prevalence of malaria among TB patients in a hospital based study in Angola using Kish Leslie formula \[[@B9], [@B35]\].

Data was entered in EpiData 3.1 and analysed using STATA 14 (StataCorp, College Station, TX, USA). The prevalence of malaria was determined as a percentage of those with malaria to the total number of study participants. Characteristics of participants with malaria/TB coinfection were summarised as frequencies and medians with corresponding interquartile ranges. The low prevalence of malaria precluded any meaningful subanalysis for significant associations of malaria/TB coinfection.

2.4. Ethics Approval and Consent to Participate {#sec2.4}
-----------------------------------------------

Study participants provided written informed consent to participate in the study. The study was approved by the Department of Internal Medicine Scientific Review Committee (SRC) and the School of Medicine Research and Ethics Committee of Makerere University College of Health Sciences (REC REF 2017-087).

3. Results {#sec3}
==========

3.1. Characteristics of Study Participants {#sec3.1}
------------------------------------------

A total of 363 bacteriologically confirmed adult pulmonary TB patients were enrolled in the study. The study flow diagram is shown in [Figure 1](#fig1){ref-type="fig"}.

Majority of the participants, 61.4% (223/363), were male; were from urban areas, 67.5% (245/363); and had at least primary level of education, 93.1% (338/363). The median age was 31 (IQR: 25-39) years and 35.8% (130/363) of the participants were HIV positive. Of the HIV positive participants, 77% (97/130) were taking cotrimoxazole prophylaxis while 49.2% (64/130) were taking antiretroviral therapy (ART). History of TB treatment was found in 15.2% (55/363), of whom 60.1% (38/55) reported having received treatment less than 3 years prior to enrolment in the study. The majority (67.5% (245/363)) of participants reported sleeping under a mosquito net the previous night. History of indoor residual spraying of accommodation units or houses in the last six months was reported by 9.4% (34/363) of the participants. History of malaria treatment in the last 1 month prior to the study was reported by 20.7% (75/363) of study participants. Anaemia was found in 58.7% (210/358) of participants. Hypochromia was found in 70.4% (252/358) of participants, microcytosis in 40.5% (145/358), and macrocytosis in 8.4% (30/358). The proportions of participants reporting cough, weight loss, night sweats, fever, chills, headache, and anorexia were (n=363) 98.1%, 84.0%, 69.1%, 60.1%, 36.1%, 32.2%, and 26.2%, respectively. Other characteristics of study participants are summarised in [Table 2](#tab2){ref-type="table"}.

3.2. Prevalence of Malaria among TB Patients {#sec3.2}
--------------------------------------------

The study found a prevalence of malaria/TB coinfection of 2.2% (8/363) among study participants. Six (75%) of these had a positive malaria antigen test (RDT) while 2 (25%) had a positive blood smear. All participants with malaria had*Plasmodium falciparum*. Alongside one with a positive RDT, the 2 participants with a positive malaria blood smear were HIV positive and had rifampicin resistance. Thus, we found a prevalence of malaria/TB/HIV triple infection of 0.83% (3/363) among the study participants. [Table 3](#tab3){ref-type="table"} shows the prevalence of malaria in the study.

3.3. Characteristics of Participants with Malaria and TB Coinfection {#sec3.3}
--------------------------------------------------------------------

We observed that participants with malaria/TB coinfection were mostly male (62.5%) and less than 35 years of age (87.5%) with no history of TB treatment (87.5%). The proportions of malaria/TB coinfected participants with cough, night sweats, fever, weight loss, chills, anorexia, and headache was 100%, 87.5%, 75%, 75%, 62.5%, 50%, and 37.5%, respectively, with a respective median duration of 48.5 (IQR: 18.5-60), 7 (IQR: 2-30), 22 (IQR: 8-30), 25.5 (IQR: 15-60), 7 (IQR: 7-14), 5.5 (IQR: 2-19.5), and 14 (IQR: 7-30) days. The median CD4 and CD8 cell counts and CD4:CD8 were 864 (IQR: 257-1281) cells/*μ*l, 527 (IQR: 443-740) cells/*μ*l, and 1.82 (IQR: 1.51-1.99), respectively. The current use of a mosquito net and history of indoor residual spraying, smoking, alcohol use, and malaria treatment in preceding month were 87.5%, 12.5%, 25.0%, 62.5%, and 25%, respectively. [Table 4](#tab4){ref-type="table"} shows other characteristics of participants with malaria/TB coinfection.

4. Discussion {#sec4}
=============

This study aimed at determining the prevalence of malaria and TB coinfection among bacteriologically confirmed adult TB patients. The study found a low prevalence of malaria among adults with bacteriologically confirmed TB patients. This could be explained by increased production of gamma interferon (IFN-*γ*), tumor necrosis factor alpha (TNF-*α*), and humoral factors induced by tuberculosis infection that are protective against malaria infection \[[@B14], [@B15], [@B37]\]. The observed low prevalence could also be due to the demographic characteristics of our study population. Our study population was an adult population from predominantly urban settings which inherently have a low prevalence of malaria \[[@B3], [@B38]\]. Further, 20% of the study participants reported a history of malaria treatment in the previous month. This too could be contributory to the low prevalence. All participants with malaria in our study had*Plasmodium falciparum*. This is expected as*P. falciparum* is the predominant*Plasmodium* species found in Uganda accounting for 97% of malaria species \[[@B3]\]. Other hospital based studies also found a low prevalence of malaria/TB coinfection as well. Anyangwe et al. (2016) found a prevalence of 1.5% in Cameron and Range et al. (2007) found it at 4.3% in Tanzania. An exception is Valadas et al. (2007) that found a prevalence of 37.5% in Angola. However, their study was retrospective and included children and clinically diagnosed TB patients, and this could have overestimated the prevalence. To the best of our knowledge, our study findings are the first to report malaria among drug resistant TB (DR-TB) patients. The relationship between DR-TB and malaria is yet to be defined and thus an interesting area for future research.

A triple infection of HIV, malaria, and DR-TB was observed in our study and we have not found other reports on the same. However, almost 20% of our study population with a GeneXpert had rifampicin resistance. Therefore, the observation of DR-TB and malaria coinfection as well as malaria/HIV/DR-TB triple infection may be coincidental. Nevertheless, DR-TB patients have high CD4 cell counts that are predominantly regulatory T-lymphocytes which reduce the expression of IFN-*γ* in these patients \[[@B40]--[@B42]\]. There is a need for further evaluation of the effect of these immune responses on the susceptibility of DR-TB patients to other infections such as malaria. Moreover, the qualitative and quantitative effects of a malaria/HIV/DR-TB triple infection on the CD4 cells are unknown. Although they did not evaluate for drug resistance, other studies in African settings report a higher prevalence of malaria/TB/HIV triple infection than ours (0.83%): 2.5% in Cameroon \[[@B6]\], 3.9% in Nigeria \[[@B4]\], and 6.0% in Tanzania \[[@B7]\]. The most recent of these studies by Anyangwe et al. (2016) found a lower prevalence (2.5%) than the older studies and Range et al. studied an HIV positive population. Not only has the HIV burden declined across sub-Saharan Africa over the years, but also West African countries like Nigeria have a higher prevalence of HIV than Uganda \[[@B43]\]. However, 77% of the HIV positive participants in our study were taking cotrimoxazole prophylaxis which confers protection against malaria \[[@B39]\]. This may explain why our prevalence of malaria/TB/HIV is lower than previous studies.

Our study had some limitations. The study was carried out at a national TB treatment referral centre and this limits generalisability of results due to referral bias. However, we found a prevalence of malaria that is comparable to other settings, and it seems that the choice of the study site have not affected the findings. The use of different laboratory results for bacillary load from different laboratories could have posed a limitation of standardisation of reporting smear results by different microscopists. However, 84% of our study participants had TB diagnosed by GeneXpert® which has standard reporting of bacillary load grade. We believe that standardisation of bacillary load did not affect our results significantly. Lastly, our study was not powered to explore associated factors. The small number of participants with malaria/TB coinfection limited any meaningful subgroup analyses.

5. Conclusion {#sec5}
=============

The prevalence of malaria among patients with bacteriologically confirmed TB is low. A further evaluation of the associated factors is warranted.

We acknowledge Mulago Hospital Haematology Laboratory for processing the study samples and particularly Mr. Bengo Derrick for reading the haematology films. We appreciate study site staff for their invaluable contribution to the success of this project.
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###### 

Grading of bacillary load by laboratory result.

  Bacillary Load Grade   Smear                            Xpert MTB/RIF®
  ---------------------- -------------------------------- ----------------
  Very Low               Scanty (1-9AFBs^¥^/100 fields)   Very Low
  Low                    1+ (1-9AFBs/10 fields)           Low
  Medium                 2+ (1-10/field)                  Medium
  Very High              3+ (\>10/field)                  High

\#: ZN: Ziehl-Neelsen.

*β*: Bacillary load by Xpert MTB/RIF® is determined by cycle threshold values.

¥: AFBs: acid fast bacilli.

###### 

Characteristics of study participants.

  Participant Characteristics                Frequency (n=363)   Percentage (%)
  ------------------------------------------ ------------------- ----------------
  *History of smoking*                                            
  Never                                      258                 71.1
  Past smoker (≥6 months ago)                50                  13.8
  Current smoker (\<6 months ago)            55                  15.2
  *Alcohol usage*                                                 
  Never                                      176                 48.5
  Past alcohol use (≥6 months ago)           58                  16.0
  Current alcohol use (\<6 months ago)       129                 35.5
  *Bacillary Load Grade (n = 351)*                                
  Very Low                                   47                  13.4
  Low                                        81                  23.1
  Medium                                     121                 34.5
  Very High                                  102                 29.1
  *Rifampicin Resistance (n=304)*                                 
  Detected                                   58                  19.1
  Indeterminate                              1                   0.3
  *Symptom Burden*                                                
  \<4 symptoms (Low)                         134                 36.9
  4-7 Symptoms (High)                        229                 63.1
  *Body Mass Index (BMI)*                                         
  Underweight                                188                 51.8
  Normal                                     158                 43.5
  Overweight                                 14                  3.9
  Obese                                      3                   0.8
  *Temperature (n=361)*                                           
  Hypothermic                                120                 33.2
  Normal                                     193                 53.5
  Hyperthermic                               48                  13.3
  *Red Blood Cell Count* ^*1*^                                    
  \<Lower Limit of Normal (LLN)              80                  22.0
  Normal                                     257                 70.8
  \>Upper Limit of Normal (ULN)              26                  7.2
  *White Blood Cell Count* ^*1*^ *(n=357)*                        
  \<LLN                                      11                  3.1
  Normal                                     237                 66.4
  \>ULN                                      109                 30.5
  *Anemia (n=358)*                                                
  Severe Anemia                              24                  6.7
  Moderate Anemia                            101                 28.2
  Mild Anemia                                85                  23.7
  Normal Hemoglobin                          148                 41.3

^1^Ranges for cell counts are for adult Ugandans \[[@B36]\].

###### 

Prevalence of malaria among patients with TB.

                                 Frequency of malaria   Prevalence (%)   95% confidence interval
  ------------------------------ ---------------------- ---------------- -------------------------
  Total population (n=363)       8                      2.20             (1.10-4.35)
  Rifampicin resistance (n=58)   3                      5.17             (1.62-15.30)
  TB/HIV co-infection (n=130)    3                      2.31             (0.74-7.00)
  TB without HIV( n=233)         5                      2.15             (0.89-5.08)

###### 

Characteristics of participants with malaria/TB co-infection.

  -----------------------------------------------------------------------------
  Characteristics of participants with malaria/TB\   Frequency\   Percentage\
  co-infection                                       (n = 8)      (%)
  -------------------------------------------------- ------------ -------------
  *Symptom burden*                                                 

  Low                                                2            25.0

  High                                               6            75.0

  *Body mass Index*                                                

  low                                                3            37.5

  Normal                                             5            62.5

  *Temperature*                                                    

  Hypothermia                                        1            12.5

  Normal                                             5            62.5

  Hyper thermic                                      2            25.0

  *Bacillary Load Grade*                                           

  Very Low                                           2            25.0

  Low                                                1            12.5

  Medium                                             3            37.5

  Very High                                          2            25.0

  *Rifampicin resistance (n = 7)*                    3            42.9

  *Anemia*                                                         

  Moderate                                           1            12.5

  Mild                                               4            50.0

  Normal hemoglobin                                  3            37.5

  *MCH*                                                            

  Normal                                             7            87.5

  Hypochromic                                        1            12.5

  *MCV*                                                            

  Microcytic                                         6            75.0

  Normal                                             2            25.0
  -----------------------------------------------------------------------------
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